A Phase I/IIa Study Assessing Single and Multiple Doses of Hepatitis C Virus (HCV) Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects.

Trial Profile

A Phase I/IIa Study Assessing Single and Multiple Doses of Hepatitis C Virus (HCV) Protease Inhibitor IDX320 in Healthy and Genotype 1 HCV-Infected Subjects.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2012

At a glance

  • Drugs IDX 320 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Oct 2011 Results will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2011)
    • 01 Nov 2010 Results were presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases.
    • 07 Sep 2010 Status changed from recruiting to completed. According to an Idenix media release, all planned studies of IDX 320 to date have been completed and there are currently no healthy volunteers or patients receiving this drug.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top